I'm LongbridgeAI, I can summarize articles.HBM Healthcare Investments invested USD 15.3 million in ADARx Pharmaceuticals' IPO, raising its total stake to USD 19.3 million and increasing its ownership to approximately 1.2%. The IPO priced shares at USD 17.00, issuing 26.25 million new shares for gross proceeds of USD 446.25 million. Post-IPO, HBM's stake was valued at USD 25.4 million based on the first-day closing price.
- HBM Healthcare Investments invested USD 15.3 million in ADARx Pharmaceuticals’ IPO, lifting total investment to USD 19.3 million. * ADARx priced the offering at USD 17.00 per share, issuing 26,250,000 new shares for USD 446.25 million gross proceeds. * Post-IPO stake rose to about 1.2%, valued at USD 25.4 million based on the first-day closing price. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Healthcare Investments AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2405906_en) on September 28, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)